Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2005

View Archived Issues

Update on TGN-255 in the prevention of thrombosis

Add-on topiramate prevents body weight gain in schizophrenics treated with antipsychotics

Novel delivery of contortrostatin provides enhanced potential for clinical development

Halofuginone modulates T-cell functional activity

Cell death pathways investigated in TH-9402-mediated cytotoxicity

BMS-593214: a novel inhibitor of FVIIa

Natriuretic peptides may help predict outcome of patients with nonischemic CHF

Urocortin 2 shows promise in the treatment of congestive heart failure

Clinical data confirm the efficacy of solifenacin in overactive bladder

AL-208 set to enter phase I trials

Enrollment completed in U.S. phase I study of cetilistat for obesity

Agenix contracts Diosynth for manufacturing of ThromboView

BioSante licenses contraceptive technology from Wake Forest University

YM BioSciences licenses oncology compounds from U. of Saskatchewan

Phase II comparative study of R-112 for allergic rhinitis opens enrollment

AmpliMed licenses FB-642 and other compounds from UTR

CytoGenix forms research collaboration with Imperial College London

Encore awarded SBIR grant for work in neuroinflammation

Cenix delivers therapeutic targets to Bayer

Phase II trial begins for OGX-011 for NSCLC

Velcura and Nippon Chemiphar collaborate on osteoporosis drugs

NS-2330 results do not warrant phase III studies in Alzheimer's, Parkinson's

Pfizer submits Sutent NDA

Bioequivalence studies continue for fixed-dose Truvada/Sustiva product

Recent patents describe new antiinfective agents

New agents for treating obesity disclosed by Procter & Gamble

Novel therapeutics for fibroproliferative diseases reported by Scios

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...